Reactivity of Patients With Borderline Personality Disorder to an Ecological Interpersonal Stress

NCT03602521 | Completed

• 1 other identifier: RECHMPL17_0394
• Study Type: interventional
• Target: 116
• Locations: 1 country
• Sites: 1

Brief Summary

Use lay language. According to the World Health Organization 1 death by suicide occurs every 40 seconds, leading suicide prevention to one of the public health priority. BPD (Borderline Personality Disorder) is a common condition affecting 6% of the population. This disorder is characterized by unstable emotions, unstable mood, difficulties with relationship and feer of abandonment. Borderline Personality Disorder is also the psychopathology the most related to suicidal attempts. Indeed, up to 50% of the patients admitted to hospital after a suicide attempt are diagnosis with a Borderline Personality Disorder Negative interpersonal events (events occurring between two people) are known as the main stressor that trigger a suicidal attempt. People with a Borderline Personality Disorder are highly sensitive to it. Moreover, neuropeptides such as oxytocin (OXT), vasopressin and opioid are known to be involved in the regulation of the emotions, especially those linked to relationship. The purpose of this study is to improve knowledge in suicidal behaviors. After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of patients with a BPD will be compared to healthy controls (HC). Clinical data reflecting how the participant is feeling will be collected as well.

Conditions

Female; Borderline Personality Disorder

Keywords

Psychiatry; Suicidal Behavior; Borderline Personality Disorder; Interpersonal Relations; Social Stress; Oxytocin; Neuropeptide

Outcome Measures

Primary Outcomes (1)

• Variation of plasma oxytocin concentrations after an interpersonal stress

  Evaluate and compare the variation of plasma oxytocin concentrations before and after an interpersonal stress of patients with BPDs vs healthy controls between pre stress to 5 minutes post interpersonal stress.

  from pre interpersonal stress to 5 minutes post stress

Secondary Outcomes (16)

• Evolution of plasma oxytocin concentrations

  from pre stress to 40 minutes post interpersonal stress

• Evolution of plasma copeptin concentrations

  from pre stress to 40 minutes post interpersonal stress

• Evolution of plasma β-endorphin concentrations

  from pre stress to 40 minutes post interpersonal stress

• self-damaging compelling needs(suicidal) pre stress

  pre stress before the interpersonal stress

• Evolution of clinical variables: self-damaging compelling needs(suicidal)

  from pre stress to 40 minutes post interpersonal stress

Study Arms (2)

BPD

EXPERIMENTAL

Blood sample After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of patients with a BPD

Other: Interpersonal stress

HC

ACTIVE COMPARATOR

Blood sample After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of healthy controls (HC) patients .without any history of psychopathology

Other: Interpersonal stress

Interventions

Interpersonal stress OTHER

Through an interview the evaluator will make a 1 to 2 pages script, written in first-person and in present tense. It will involve an interpersonal conflict between the participants and the person who once trigger their feeling of abandonment. After reading the script the participants will have to close their eyes and imagine the event as if was happening to them, now, in real time, and think about it during 3 minutes. To evaluate the stress efficiency, the evaluator will ask 2 questions : * 1\) "from 0 (no distress at all) to 10 (maximal unimaginable distress), to wich point this script bring distress to you?" * 2\) "from 0 (I can not at all) to 10 (I can completely), to wich point are you able to imagine the scenario in real time, as if you were living it?"

BPD; HC

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• If taking hormonal contraceptive: able to participate between the 3rd and 18th day after taking the contraceptive If not taking hormonal contraceptive: able to participate between the 5th and 12th day after the first day of the last period
• Able to understand the nature, purpose and methodology of the study
• Having signed the informed consent
• To be affiliated to a social security scheme
• Borderline Personality Disorder(BPD) :
• \- Clinical diagnosis of BPD using the SCID II (Structured Clinical Interview for DSM-IV-TR Axis II Personality Disorders)
• Healthy controls:
• \- No personal history of psychiatric disorders (Axis I ) defined by the MINI International Neuropsychiatric Interview according to the DSM-5 criteria

You may not qualify if:

• Refusal of participation
• Subject protected by law (guardianship)
• Life time diagnosis of schizoaffective disorder or schizophrenia
• Pregnant or breastfeeding women
• Deprived of liberty Subject (by judicial or administrative decision)
• Having reached the maximum annual amount of allowances of € 4,500

Sponsors & Collaborators

• University Hospital, Montpellier: lead

Study Sites (1)

Hospital Lapeyronie

Montpellier, 34295, France

Location

MeSH Terms

Conditions

Borderline Personality Disorder

Condition Hierarchy (Ancestors)

Personality Disorders; Mental Disorders

Study Officials

• Deborah Ducasse, MD

  Urgence psychiatric lapeyonie Hospital Montpellier

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 18, 2018
• First Posted: July 27, 2018
• Study Start: February 27, 2019
• Primary Completion: August 18, 2023
• Study Completion: August 18, 2023
• Last Updated: December 20, 2023

Record last verified: 2023-06

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)